Financials data is unavailable for this security.
View more
Year on year Integra Lifesciences Holdings Corp 's net income fell -62.48% from 180.55m to 67.74m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 38.25% to 39.09%.
Gross margin | 61.54% |
---|---|
Net profit margin | 1.51% |
Operating margin | 4.04% |
Return on assets | 0.60% |
---|---|
Return on equity | 1.47% |
Return on investment | 0.66% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Integra Lifesciences Holdings Corp fell by 180.26m. However, the company earned 139.96m from its operations for a Cash Flow Margin of 9.08%. In addition the company used 94.18m on investing activities and also paid 229.93m in financing cash flows.
Cash flow per share | 1.95 |
---|---|
Price/Cash flow per share | 8.89 |
Book value per share | 19.77 |
---|---|
Tangible book value per share | -10.19 |
More ▼
Balance sheet in USDView more
Current ratio | 3.39 |
---|---|
Quick ratio | 2.10 |
Total debt/total equity | 1.19 |
---|---|
Total debt/total capital | 0.5433 |
More ▼
Growth rates in USD
SmartText is unavailable
EPS growth(5 years) | 3.10 |
---|---|
EPS (TTM) vs TTM 1 year ago | -81.27 |